United Therapeutics (UTHR) Competitors $358.93 -7.46 (-2.04%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends UTHR vs. ALNY, BIIB, NBIX, INCY, BMRN, EXAS, EXEL, RGEN, HALO, and MDGLShould you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. United Therapeutics vs. Alnylam Pharmaceuticals Biogen Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exact Sciences Exelixis Repligen Halozyme Therapeutics Madrigal Pharmaceuticals United Therapeutics (NASDAQ:UTHR) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation. Which has more risk and volatility, UTHR or ALNY? United Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Is UTHR or ALNY more profitable? United Therapeutics has a net margin of 40.31% compared to Alnylam Pharmaceuticals' net margin of -15.86%. United Therapeutics' return on equity of 19.22% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets United Therapeutics40.31% 19.22% 16.15% Alnylam Pharmaceuticals -15.86%N/A -8.38% Does the media favor UTHR or ALNY? In the previous week, Alnylam Pharmaceuticals had 18 more articles in the media than United Therapeutics. MarketBeat recorded 32 mentions for Alnylam Pharmaceuticals and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.17 beat Alnylam Pharmaceuticals' score of 0.70 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 11 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in UTHR or ALNY? 94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 11.9% of United Therapeutics shares are held by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, UTHR or ALNY? United Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnited Therapeutics$2.33B6.89$984.80M$22.7715.76Alnylam Pharmaceuticals$1.83B17.37-$440.24M-$2.62-94.00 Do analysts rate UTHR or ALNY? United Therapeutics presently has a consensus price target of $378.36, indicating a potential upside of 5.41%. Alnylam Pharmaceuticals has a consensus price target of $298.61, indicating a potential upside of 21.25%. Given Alnylam Pharmaceuticals' higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United Therapeutics 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.73Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.72 Does the MarketBeat Community believe in UTHR or ALNY? Alnylam Pharmaceuticals received 543 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 62.50% of users gave United Therapeutics an outperform vote. CompanyUnderperformOutperformUnited TherapeuticsOutperform Votes59562.50% Underperform Votes35737.50% Alnylam PharmaceuticalsOutperform Votes113876.17% Underperform Votes35623.83% SummaryUnited Therapeutics beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks. Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UTHR vs. The Competition Export to ExcelMetricUnited TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.29B$6.35B$5.24B$8.98BDividend YieldN/A2.94%5.13%4.03%P/E Ratio15.764.7861.7913.70Price / Sales6.89317.971,258.3278.91Price / Cash16.5261.4443.8235.97Price / Book2.826.055.324.80Net Income$984.80M$154.62M$122.68M$224.91M7 Day Performance-1.65%-1.70%-0.21%1.47%1 Month Performance0.39%2.75%3.72%4.66%1 Year Performance63.81%2.60%27.18%20.83% United Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UTHRUnited Therapeutics4.9245 of 5 stars$358.93-2.0%$378.36+5.4%+61.5%$16.29B$2.33B15.761,168Analyst UpgradeInsider TradeShort Interest ↓News CoveragePositive NewsALNYAlnylam Pharmaceuticals4.4437 of 5 stars$256.74+7.9%$298.61+16.3%+30.6%$33.11B$2.09B-97.992,100Analyst RevisionNews CoverageBIIBBiogen4.7143 of 5 stars$149.34+0.3%$230.00+54.0%-42.7%$21.76B$9.61B13.498,720Short Interest ↑NBIXNeurocrine Biosciences4.9149 of 5 stars$142.21+0.9%$164.81+15.9%+4.5%$14.40B$2.24B38.131,200Insider TradeNews CoverageINCYIncyte4.7412 of 5 stars$72.50+2.8%$76.29+5.2%+17.0%$13.97B$4.08B517.892,524Analyst ForecastShort Interest ↓News CoverageBMRNBioMarin Pharmaceutical4.9993 of 5 stars$66.80-0.9%$94.20+41.0%-34.1%$12.73B$2.75B40.003,401Options VolumeNews CoverageEXASExact Sciences4.7666 of 5 stars$57.37+1.5%$72.94+27.1%-19.2%$10.62B$2.69B-49.036,600News CoverageEXELExelixis4.5431 of 5 stars$35.24-2.2%$33.75-4.2%+60.6%$10.06B$2.08B22.591,310Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageRGENRepligen3.7334 of 5 stars$157.76+1.9%$185.20+17.4%-6.0%$8.84B$639.92M-426.372,020HALOHalozyme Therapeutics4.5953 of 5 stars$53.90+2.1%$60.89+13.0%+52.1%$6.86B$947.36M17.85390Short Interest ↑Analyst RevisionMDGLMadrigal Pharmaceuticals4.5592 of 5 stars$298.94-11.8%$350.83+17.4%+22.4%$6.52B$76.81M-11.9290Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading Volume Related Companies and Tools Related Companies ALNY Alternatives BIIB Alternatives NBIX Alternatives INCY Alternatives BMRN Alternatives EXAS Alternatives EXEL Alternatives RGEN Alternatives HALO Alternatives MDGL Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UTHR) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UTHR Stock Alerts